Categories AlphaGraphs, Earnings, Health Care
Bristol Myers (BMY) stock gains after Q4 results beat Street view
Bristol-Myers Squibb Company (NYSE: BMY) Thursday reported stronger-than-expected fourth-quarter results. The company’s stock gained in the pre-market session soon after the announcement.
The pharmaceutical company reported a 39% growth in fourth-quarter revenue of $11.1 billion, which surpassed Wall Street’s consensus forecast. Consequently, adjusted earnings rose 20% annually to $1.46 per share from $1.22 per share in the fourth quarter of 2019.
On an unadjusted basis, it was a net loss of $10.0 billion or $4.45 per share, compared to a loss of $1.1 billion or $0.55 per share last year.
Read management/analysts’ comments on Bristol Myers’ Q4 report
BMY shares gained 1% immediately after the announcement early Thursday. The stock had closed the previous session lower.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on